Beyond serotonin: newer antidepressants in the future

References

• Undurraga J, Baldessarini RJ. Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review. Neuropsychopharmacology. 2012;37:851–864.
   PubMed Web of Science ®Google Scholar
• Tedeschini E, Levkovitz Y, Iovieno N, et al. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials. J Clin Psychiatry. 2011;72:1660–1668. .
   PubMed Web of Science ®Google Scholar
• Gaynes BN, Warden D, Trivedi MH, et al. What did STAR* D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Services. 2009;60:1439–1445. .
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR* D: implications for clinical practice. Am J Psychiatry. 2006;163:28–40.
   PubMed Web of Science ®Google Scholar
• Souery D, Papakostas GI, Trivedi MH. Treatment-resistant depression. J Clin Psychiatry. 2006;67(Suppl 6):16–22.
   PubMed Web of Science ®Google Scholar
• Malhi GS, Byrow Y. Is treatment-resistant depression a useful concept? Evid Based Ment Health. 2016;19:1–3. .
   PubMed Web of Science ®Google Scholar
• Malhi GS, Parker GB, Crawford J, et al. Treatment-resistant depression: resistant to definition? Acta Psychiatr Scand. 2005;112:302–309.
   PubMed Web of Science ®Google Scholar
• Conway CR, George MS, Sackeim HA. Toward an evidence-based, operational definition of treatment-resistant depression: when enough is enough. JAMA Psychiatry. 2017;74:9-10.
   PubMed Web of Science ®Google Scholar
• Transcript on Treatment Resistant Depression. Centers for Medicare & Medicaid services; 2016. Available from: https://www.cms.gov/Regulations-and-Guidance/Guidance/FACA/downloads/id71d.pdf
   Google Scholar
• Greenberg PE, Fournier AA, Sisitsky T, et al. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015;76:155–162.
   PubMed Web of Science ®Google Scholar
• Olchanski N, McInnis Myers M, Halseth M, et al. The economic burden of treatment-resistant depression. Clin Ther. 2013;35:512–522.
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Stewart JW, et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry. 2011;168:689–701.
   PubMed Web of Science ®Google Scholar
• CERC-301. Cerecor; 2016. Available from: http://ir.cerecor.com/press-releases/detail/30/cerecor-reports-top-line-data-from-cerc-301-phase-2-study
   Google Scholar
• Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology. 2012;62:63–77.
   PubMed Web of Science ®Google Scholar
• Popoli M, Yan Z, McEwen BS, et al. The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nat Reviews Neurosci. 2012;13:22–37.
   Web of Science ®Google Scholar
• Musazzi L, Treccani G, Popoli M. Functional and structural remodeling of glutamate synapses in prefrontal and frontal cortex induced by behavioral stress. Front Psychiatry. 2015;6:60.
   PubMed Web of Science ®Google Scholar
• Gao SF, Bao AM. Corticotropin-releasing hormone, glutamate, and gamma-aminobutyric acid in depression. Neuroscientist. 2011;17:124–144.
   PubMed Web of Science ®Google Scholar
• Yuan TF, Hou G. The effects of stress on glutamatergic transmission in the brain. Mol Neurobiol. 2015;51:1139–1143.
   PubMed Web of Science ®Google Scholar
• Graybeal C, Kiselycznyk C, Holmes A. Stress-induced deficits in cognition and emotionality: a role of glutamate. Curr Top Behav Neurosci. 2012;12:189–207.
   PubMedGoogle Scholar
• Musazzi L, Racagni G, Popoli M. Stress, glucocorticoids and glutamate release: effects of antidepressant drugs. Neurochem Int. 2011;59:138–149.
   PubMed Web of Science ®Google Scholar
• Douglas RJ, Martin KA. Mapping the matrix: the ways of neocortex. Neuron. 2007;56:226–238.
   PubMed Web of Science ®Google Scholar
• Frye MA, Tsai GE, Huggins T, et al. Low cerebrospinal fluid glutamate and glycine in refractory affective disorder. Biol Psychiatry. 2007;61:162–166.
   PubMed Web of Science ®Google Scholar
• Levine J, Panchalingam K, Rapoport A, et al. Increased cerebrospinal fluid glutamine levels in depressed patients. Biol Psychiatry. 2000;47:586–593.
   PubMed Web of Science ®Google Scholar
• Choudary PV, Molnar M, Evans SJ, et al. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci USA. 2005;102:15653–15658.
   PubMed Web of Science ®Google Scholar
• Machado-Vieira R, Manji HK, Zarate CA. The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist. 2009;15:525–539.
   PubMed Web of Science ®Google Scholar
• Hillhouse TM, Porter JH. A brief history of the development of antidepressant drugs: from monoamines to glutamate. Exp Clin Psychopharmacol. 2015;23:1–21.
   PubMed Web of Science ®Google Scholar
• Dang YH, Ma XC, Zhang JC, et al. Targeting of NMDA receptors in the treatment of major depression. Curr Pharm Des. 2014;20:5151–5159.
   PubMed Web of Science ®Google Scholar
• Hashimoto K. The role of glutamate on the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:1558–1568.
   PubMed Web of Science ®Google Scholar
• Schatzberg AF. Development of new psychopharmacological agents for depression and anxiety. Psychiatr Clin North Am. 2015;38:379–393.
   PubMed Web of Science ®Google Scholar
• Mathews DC, Henter ID, Zarate CA. Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date. Drugs. 2012;72:1313–1333.
   PubMed Web of Science ®Google Scholar
• Reus GZ, Abelaira HM, Tuon T, et al. Glutamatergic NMDA receptor as therapeutic target for depression. Adv Protein Chem Struct Biol. 2016;103:169–202.
   PubMed Web of Science ®Google Scholar
• Wang J, Jing L, Toledo-Salas JC, et al. Rapid-onset antidepressant efficacy of glutamatergic system modulators: the neural plasticity hypothesis of depression. Neurosci Bull. 2015;31:75–86.
   PubMed Web of Science ®Google Scholar
• Krystal JH, Sanacora G, Duman RS. Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry. 2013;73:1133–1141.
   PubMed Web of Science ®Google Scholar
• Niciu MJ, Ionescu DF, Richards EM, et al. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder. J Neural Transm. 2014;121:907–924.
   PubMed Web of Science ®Google Scholar
• Chitty KM, Lagopoulos J, Lee RS, et al. A systematic review and meta-analysis of proton magnetic resonance spectroscopy and mismatch negativity in bipolar disorder. Eur Neuropsychopharmacol. 2013;23:1348–1363.
   PubMed Web of Science ®Google Scholar
• Gigante AD, Bond DJ, Lafer B, et al. Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a meta-analysis. Bipolar Disord. 2012;14:478–487.
   PubMed Web of Science ®Google Scholar
• Arnone D, Mumuni AN, Jauhar S, et al. Indirect evidence of selective glial involvement in glutamate-based mechanisms of mood regulation in depression: meta-analysis of absolute prefrontal neuro-metabolic concentrations. Eur Neuropsychopharmacol. 2015;25:1109–1117.
   PubMed Web of Science ®Google Scholar
• Lee HK, Kirkwood A. AMPA receptor regulation during synaptic plasticity in hippocampus and neocortex. Semin Cell Dev Biol. 2011;22:514–520.
   PubMed Web of Science ®Google Scholar
• Musazzi L, Treccani G, Mallei A, et al. The action of antidepressants on the glutamate system: regulation of glutamate release and glutamate receptors. Biol Psychiatry. 2013;73:1180–1188.
   PubMed Web of Science ®Google Scholar
• Niswender CM, Conn PJ. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol. 2010;50:295–322.
   PubMed Web of Science ®Google Scholar
• Niciu MJ, Ionescu DF, Mathews DC, et al. Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part I: major depressive disorder. CNS Spectrums. 2013;18:231–241.
   PubMed Web of Science ®Google Scholar
• Monaghan DT, Jane DE. Pharmacology of NMDA receptors. In: Van Dongen AM, editor. Biology of the NMDA receptor. Boca Raton (FL): Frontiers in Neuroscience; 2009.
   Google Scholar
• Paoletti P, Bellone C, Zhou Q. NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci. 2013;14:383–400.
   PubMed Web of Science ®Google Scholar
• Duman RS. Neurobiology of stress, depression, and rapid acting antidepressants: remodeling synaptic connections. Depress Anxiety. 2014;31:291–296.
   PubMed Web of Science ®Google Scholar
• Hardingham GE, Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci. 2010;11:682–696.
   PubMed Web of Science ®Google Scholar
• Chong C, Schug SA, Page-Sharp M, et al. Development of a sublingual/oral formulation of ketamine for use in neuropathic pain: preliminary findings from a three-way randomized, crossover study. Clin Drug Investig. 2009;29:317–324.
   PubMed Web of Science ®Google Scholar
• Coyle CM, Laws KR. The use of ketamine as an antidepressant: a systematic review and meta-analysis. Hum Psychopharmacol. 2015;30:152–163.
   PubMed Web of Science ®Google Scholar
• Caddy C, Giaroli G, White TP, et al. Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy. Ther Advances Psychopharmacol. 2014;4:75–99.
   PubMedGoogle Scholar
• Fond G, Loundou A, Rabu C, et al. Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology. 2014;231:3663–3676.
   PubMed Web of Science ®Google Scholar
• Singh JB, Fedgchin M, Daly EJ, et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry. 2016;173:816–826.
   PubMed Web of Science ®Google Scholar
• Niesters M, Martini C, Dahan A. Ketamine for chronic pain: risks and benefits. Br J Clin Pharmacol. 2014;77:357–367.
   PubMed Web of Science ®Google Scholar
• Newport DJ, Carpenter LL, McDonald WM, et al. Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry. 2015;172:950–966.
   PubMed Web of Science ®Google Scholar
• McGirr A, Berlim MT, Bond DJ, et al. A systematic review and meta-analysis of randomized controlled trials of adjunctive ketamine in electroconvulsive therapy: efficacy and tolerability. J Psychiatr Res. 2015;62:23–30.
   PubMed Web of Science ®Google Scholar
• Wang X, Chen Y, Zhou X, et al. Effects of propofol and ketamine as combined anesthesia for electroconvulsive therapy in patients with depressive disorder. J Ect. 2012;28:128–132.
   PubMed Web of Science ®Google Scholar
• Loo CK, Katalinic N, Garfield JB, et al. Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial. J Affect Disord. 2012;142:233–240.
   PubMed Web of Science ®Google Scholar
• Yoosefi A, Sepehri AS, Kargar M, et al. Comparing effects of ketamine and thiopental administration during electroconvulsive therapy in patients with major depressive disorder: a randomized, double-blind study. J Ect. 2014;30:15–21.
   PubMed Web of Science ®Google Scholar
• Abdallah CG, Fasula M, Kelmendi B, et al. Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting. J Ect. 2012;28:157–161.
   PubMed Web of Science ®Google Scholar
• Jarventausta K, Chrapek W, Kampman O, et al. Effects of S-ketamine as an anesthetic adjuvant to propofol on treatment response to electroconvulsive therapy in treatment-resistant depression: a randomized pilot study. J Ect. 2013;29:158–161.
   PubMed Web of Science ®Google Scholar
• Abdallah CG, Adams TG, Kelmendi B, et al. Ketamine’s mechanism of action: a path to rapid-acting antidepressants. Depress Anxiety. 2016;33:689–697.
   PubMed Web of Science ®Google Scholar
• Abdallah CG, Averill LA, Krystal JH. Ketamine as a promising prototype for a new generation of rapid-acting antidepressants. Ann NY Acad Sci. 2015;1344:66–77.
   PubMed Web of Science ®Google Scholar
• Lepack AE, Fuchikami M, Dwyer JM, et al. BDNF release is required for the behavioral actions of ketamine. Int J Neuropsychopharmacol. 2014;18.
   PubMed Web of Science ®Google Scholar
• Autry AE, Adachi M, Nosyreva E, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. 2011;475:91–95. .
   PubMed Web of Science ®Google Scholar
• Li N, Lee B, Liu RJ, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329:959–964. .
   PubMed Web of Science ®Google Scholar
• Murrough JW, Collins KA, Fields J, et al. Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder. Transl Psychiatry. 2015;5:e509.
   PubMed Web of Science ®Google Scholar
• Salvadore G, Cornwell BR, Colon-Rosario V, et al. Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry. 2009;65:289–295.
   PubMed Web of Science ®Google Scholar
• Salvadore G, Cornwell BR, Sambataro F, et al. Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology. 2010;35:1415–1422.
   PubMed Web of Science ®Google Scholar
• Di Lazzaro V, Oliviero A, Profice P, et al. Ketamine increases human motor cortex excitability to transcranial magnetic stimulation. J Physiol. 2003;547:485–496.
   PubMed Web of Science ®Google Scholar
• Duncan WC, Sarasso S, Ferrarelli F, et al. Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Int J Neuropsychopharmacol. 2013;16:301–311.
   PubMed Web of Science ®Google Scholar
• Bowdle TA, Radant AD, Cowley DS, et al. Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesiology. 1998;88:82–88.
   PubMed Web of Science ®Google Scholar
• Pomarol-Clotet E, Honey GD, Murray GK, et al. Psychological effects of ketamine in healthy volunteers. Phenomenological study. Br J Psychiatry. 2006;189:173–179.
   PubMed Web of Science ®Google Scholar
• Cvrcek P. Side effects of ketamine in the long-term treatment of neuropathic pain. Pain Med. 2008;9:253–257.
   PubMed Web of Science ®Google Scholar
• Morgan CJ, Curran HV. Acute and chronic effects of ketamine upon human memory: a review. Psychopharmacology (Berl). 2006;188:408–424.
   PubMed Web of Science ®Google Scholar
• Sigtermans M, Dahan A, Mooren R, et al. S(+)-ketamine effect on experimental pain and cardiac output: a population pharmacokinetic-pharmacodynamic modeling study in healthy volunteers. Anesthesiology. 2009;111:892–903. .
   PubMed Web of Science ®Google Scholar
• Zhu W, Ding Z, Zhang Y, et al. Risks associated with misuse of ketamine as a rapid-acting antidepressant. Neurosci Bull. 2016;32:557–564.
   PubMed Web of Science ®Google Scholar
• Middela S, Pearce I. Ketamine-induced vesicopathy: a literature review. Int J Clin Pract. 2011;65:27–30.
   PubMed Web of Science ®Google Scholar
• Nishimura M, Sato K. Ketamine stereoselectively inhibits rat dopamine transporter. Neurosci Lett. 1999;274:131–134.
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Kakiuchi T, Ohba H, et al. Reduction of dopamine D2/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys. Eur Arch Psychiatry Clin Neurosci. 2017;267:173-176.
   PubMed Web of Science ®Google Scholar
• Vollenweider FX, Leenders KL, Oye I, et al. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol. 1997;7:25–38.
   PubMed Web of Science ®Google Scholar
• Oye I, Paulsen O, Maurset A. Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. J Pharmacol Exp Ther. 1992;260:1209–1213.
   PubMed Web of Science ®Google Scholar
• Kohrs R, Durieux ME. Ketamine: teaching an old drug new tricks. Anesth Analg. 1998;87:1186–1193.
   PubMed Web of Science ®Google Scholar
• Muller J, Pentyala S, Dilger J, et al. Ketamine enantiomers in the rapid and sustained antidepressant effects. Ther Advances Psychopharmacol. 2016;6:185–192.
   PubMed Web of Science ®Google Scholar
• Singh JB, Fedgchin M, Daly E, et al. Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study. Biol Psychiatry. 2015;80:424-431.
   PubMed Web of Science ®Google Scholar
• Yang C, Shirayama Y, Zhang JC, et al. R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry. 2015;5:e632.
   PubMed Web of Science ®Google Scholar
• Esketamine Breakthrough Designation. Janssen; 2016. Available from: http://www.jnj.com/news/all/Esketamine-Receives-Breakthrough-Therapy-Designation-from-US-Food-and-Drug-Administration-for-Major-Depressive-Disorder-with-Imminent-Risk-for-Suicide.
   Google Scholar
• Bui KH, Zhou D, Agbo F, et al. Effect of multiple intravenous doses of lanicemine (AZD6765) on the pharmacokinetics of midazolam in healthy subjects. J Clin Pharmacol. 2015;55:1024–1030.
   PubMed Web of Science ®Google Scholar
• Downey D, Dutta A, McKie S, et al. Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate. Eur Neuropsychopharmacol. 2016;26:994–1003.
   PubMed Web of Science ®Google Scholar
• Guo J, Zhou D, Grimm SW, et al. Pharmacokinetics, metabolism and excretion of [(14)C]-lanicemine (AZD6765), a novel low-trapping N-methyl-d-aspartic acid receptor channel blocker, in healthy subjects. Xenobiotica. 2015;45:244–255.
   PubMed Web of Science ®Google Scholar
• Sanacora G, Smith MA, Pathak S, et al. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol Psychiatry. 2014;19:978–985.
   PubMed Web of Science ®Google Scholar
• AZD6423. Astrazeneca; 2014. Available from: https://neurogram.wordpress.com/2014/02/06/astrazeneca-good-news-bad-news/
   Google Scholar
• Graef JD, Newberry K, Newton A, et al. Effect of acute NR2B antagonist treatment on long-term potentiation in the rat hippocampus. Brain Res. 2015;1609:31–39.
   PubMed Web of Science ®Google Scholar
• Preskorn SH, Baker B, Kolluri S, et al. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol. 2008;28:631–637.
   PubMed Web of Science ®Google Scholar
• Hashimoto K. Comments on an innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101606 in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol. 2009;29:411–412; author reply 2.
   PubMed Web of Science ®Google Scholar
• Mott DD, Doherty JJ, Zhang S, et al. Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition. Nat Neurosci. 1998;1:659–667.
   PubMed Web of Science ®Google Scholar
• Ibrahim L, Diaz Granados N, Jolkovsky L, et al. A randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J Clin Psychopharmacol. 2012;32:551–557.
   PubMed Web of Science ®Google Scholar
• Garner R, Gopalakrishnan S, McCauley JA, et al. Preclinical pharmacology and pharmacokinetics of CERC-301, a GluN2B-selective N-methyl-D-aspartate receptor antagonist. Pharmacol Res Perspect. 2015;3:e00198.
   PubMed Web of Science ®Google Scholar
• Stroebel D, Buhl DL, Knafels JD, et al. A novel binding mode reveals two distinct classes of NMDA receptor GluN2B-selective antagonists. Mol Pharmacol. 2016;89:541–551.
   PubMed Web of Science ®Google Scholar
• EVT-101. Evotec; 2009. Available from: https://www.evotec.com/uploads/cms_article/1520/Evotec_and_Roche_to_Develop_EVT_101.pdf
   Google Scholar
• Heresco-Levy U, Gelfin G, Bloch B, et al. A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression. Int J Neuropsychopharmacol. 2013;16:501–506.
   PubMed Web of Science ®Google Scholar
• Heresco-Levy U, Javitt DC, Gelfin Y, et al. Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder. J Affect Disord. 2006;93:239–243.
   PubMed Web of Science ®Google Scholar
• Zhang XL, Sullivan JA, Moskal JR, et al. A NMDA receptor glycine site partial agonist, GLYX-13, simultaneously enhances LTP and reduces LTD at Schaffer collateral-CA1 synapses in hippocampus. Neuropharmacology. 2008;55:1238–1250.
   PubMed Web of Science ®Google Scholar
• Burgdorf J, Zhang XL, Weiss C, et al. The N-methyl-D-aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging rats. Neurobiol Aging. 2011;32:698–706.
   PubMed Web of Science ®Google Scholar
• Preskorn S, Macaluso M, Mehra DO, et al. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. J Psychiatr Pract. 2015;21:140–149.
   PubMed Web of Science ®Google Scholar
• Burch R. Phase 2 data for GLYX13. 2012. In: Proceedings of the 51st American College of Neuropsychopharmacology (ACNP) Conference; 2012 Dec 2-6; Hollywood, FL. Publisher: American College of Neuropsychopharmacology.
   Google Scholar
• Fuxe K, Borroto-Escuela DO. Basimglurant for treatment of major depressive disorder: a novel negative allosteric modulator of metabotropic glutamate receptor 5. Expert Opin Investig Drugs. 2015;24:1247–1260.
   PubMed Web of Science ®Google Scholar
• Jaeschke G, Kolczewski S, Spooren W, et al. Metabotropic glutamate receptor 5 negative allosteric modulators: discovery of 2-chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (basimglurant, RO4917523), a promising novel medicine for psychiatric diseases. J Med Chem. 2015;58:1358–1371.
   PubMed Web of Science ®Google Scholar
• Lindemann L, Porter RH, Scharf SH, et al. Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression. J Pharmacol Exp Ther. 2015;353:213–233.
   PubMed Web of Science ®Google Scholar
• Quiroz JA, Tamburri P, Deptula D, et al. Efficacy and safety of basimglurant as adjunctive therapy for major depression: a randomized clinical trial. JAMA Psychiatry. 2016;73:675–684.
   PubMed Web of Science ®Google Scholar
• Garay RP, Citrome L, Grossberg GT, et al. Investigational drugs for treating agitation in persons with dementia. Expert Opin Investig Drugs. 2016;25:973–983.
   PubMed Web of Science ®Google Scholar
• Lauterbach EC. Treatment resistant depression with loss of antidepressant response: rapid-acting antidepressant action of dextromethorphan, a possible treatment bridging molecule. Psychopharmacol Bull. 2016;46:53–58.
   PubMedGoogle Scholar
• Zanos P, Piantadosi SC, Wu HQ, et al. The prodrug 4-chlorokynurenine causes ketamine-like antidepressant effects, but not side effects, by NMDA/GlycineB-site inhibition. J Pharmacol Exp Ther. 2015;355:76–85.
   PubMed Web of Science ®Google Scholar
• Liu BB, Luo L, Liu XL, et al. 7-Chlorokynurenic acid (7-CTKA) produces rapid antidepressant-like effects: through regulating hippocampal microRNA expressions involved in TrkB-ERK/Akt signaling pathways in mice exposed to chronic unpredictable mild stress. Psychopharmacology (Berl). 2015;232:541–550.
   PubMed Web of Science ®Google Scholar
• AV-101. Vistagen; 2017. Available from: http://www.vistagen.com/pipeline/av-101
   Google Scholar
• Ehrich E, Turncliff R, Du Y, et al. Evaluation of opioid modulation in major depressive disorder. Neuropsychopharmacology. 2015;40:1448–1455. .
   PubMed Web of Science ®Google Scholar
• Kennedy SE, Koeppe RA, Young EA, et al. Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch Gen Psychiatry. 2006;63:1199–1208.
   PubMed Web of Science ®Google Scholar
• Carlezon WA Jr., Beguin C, Knoll AT, et al. Kappa-opioid ligands in the study and treatment of mood disorders. Pharmacol Ther. 2009;123:334–343.
   PubMed Web of Science ®Google Scholar
• Negus SS, Morrissey EM, Rosenberg M, et al. Effects of kappa opioids in an assay of pain-depressed intracranial self-stimulation in rats. Psychopharmacology (Berl). 2010;210:149–159.
   PubMed Web of Science ®Google Scholar
• Tomasiewicz HC, Todtenkopf MS, Chartoff EH, et al. The kappa-opioid agonist U69593 blocks cocaine-induced enhancement of brain stimulation reward. Biol Psychiatry. 2008;64:982–988.
   PubMed Web of Science ®Google Scholar
• Carlezon WA Jr., Krystal AD. Kappa-opioid antagonists for psychiatric disorders: from bench to clinical trials. Depress Anxiety. 2016;33:895–906.
   PubMed Web of Science ®Google Scholar
• Carlezon WA Jr., Thome J, Olson VG, et al. Regulation of cocaine reward by CREB. Science. 1998;282:2272–2275.
   PubMed Web of Science ®Google Scholar
• Carroll FI, Carlezon WA Jr. Development of kappa opioid receptor antagonists. J Med Chem. 2013;56:2178–2195. .
   PubMed Web of Science ®Google Scholar
• Yovell Y, Bar G, Mashiah M, et al. Ultra-low-dose buprenorphine as a time-limited treatment for severe suicidal ideation: a randomized controlled trial. Am J Psychiatry. 2016;173:491–498.
   PubMed Web of Science ®Google Scholar
• Wentland MP, Lou R, Lu Q, et al. Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009;19:203–208.
   PubMed Web of Science ®Google Scholar
• Wentland MP, Lu Q, Lou R, et al. Synthesis and opioid receptor binding properties of a highly potent 4-hydroxy analogue of naltrexone. Bioorg Med Chem Lett. 2005;15:2107–2110.
   PubMed Web of Science ®Google Scholar
• Fava M, Memisoglu A, Thase ME, et al. Opioid modulation with buprenorphine/samidorphan as adjunctive treatment for inadequate response to antidepressants: a randomized double-blind placebo-controlled trial. Am J Psychiatry. 2016;173:499–508.
   PubMed Web of Science ®Google Scholar
• Lowe SL, Wong CJ, Witcher J, et al. Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects. J Clin Pharmacol. 2014;54:968–978.
   PubMed Web of Science ®Google Scholar
• Janowsky DS, el-Yousef MK, Davis JM, et al. Cholinergic reversal of manic symptoms. Lancet. 1972;1:1236–1237.
   PubMed Web of Science ®Google Scholar
• Risch SC, Kalin NH, Janowsky DS. Cholinergic challenges in affective illness: behavioral and neuroendocrine correlates. J Clin Psychopharmacol. 1981;1:186–192.
   PubMed Web of Science ®Google Scholar
• Carroll BJ, Frazer A, Schless A, et al. Cholinergic reversal of manic symptoms. Lancet. 1973;1:427–428.
   PubMed Web of Science ®Google Scholar
• Furey ML, Drevets WC. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry. 2006;63:1121–1129.
   PubMed Web of Science ®Google Scholar
• Drevets WC, Furey ML. Replication of scopolamine’s antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol Psychiatry. 2010;67:432–438.
   PubMed Web of Science ®Google Scholar
• Furey ML, Khanna A, Hoffman EM, et al. Scopolamine produces larger antidepressant and antianxiety effects in women than in men. Neuropsychopharmacology. 2010;35:2479–2488.
   PubMed Web of Science ®Google Scholar
• Drevets WC, Zarate CA Jr., Furey ML. Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review. Biol Psychiatry. 2013;73:1156–1163.
   PubMed Web of Science ®Google Scholar
• Voleti B, Navarria A, Liu RJ, et al. Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. Biol Psychiatry. 2013;74:742–749.
   PubMed Web of Science ®Google Scholar
• Shelton RC, Pencina MJ, Barrentine LW, et al. Association of obesity and inflammatory marker levels on treatment outcome: results from a double-blind, randomized study of adjunctive L-methylfolate calcium in patients with MDD who are inadequate responders to SSRIs. J Clin Psychiatry. 2015;76:1635–1641.
   PubMed Web of Science ®Google Scholar
• Kim YK, Won E. The influence of stress on neuroinflammation and alterations in brain structure and function in major depressive disorder. Behav Brain Res. 2017;329:6–11.
   PubMed Web of Science ®Google Scholar
• Sharma A. Systems genomics support for immune and inflammation hypothesis of depression. Curr Neuropharmacol. 2016;14:749–758.
   PubMed Web of Science ®Google Scholar
• Spalletta G, Bossu P, Ciaramella A, et al. The etiology of poststroke depression: a review of the literature and a new hypothesis involving inflammatory cytokines. Mol Psychiatry. 2006;11:984–991.
   PubMed Web of Science ®Google Scholar
• Maes M, Yirmyia R, Noraberg J, et al. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis. 2009;24:27–53.
   PubMed Web of Science ®Google Scholar
• Liu Y, Ho RC, Mak A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-alpha) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord. 2012;139:230–239.
   PubMed Web of Science ®Google Scholar
• Fond G, Hamdani N, Kapczinski F, et al. Effectiveness and tolerance of anti-inflammatory drugs’ add-on therapy in major mental disorders: a systematic qualitative review. Acta Psychiatr Scand. 2014;129:163–179.
   PubMed Web of Science ®Google Scholar
• Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70:31–41.
   PubMed Web of Science ®Google Scholar
• Miller LL, Leitl MD, Banks ML, et al. Effects of the triple monoamine uptake inhibitor amitifadine on pain-related depression of behavior and mesolimbic dopamine release in rats. Pain. 2015;156:175–184.
   PubMed Web of Science ®Google Scholar
• Marks DM, Abramowitz JS, Spielmans GI. Concerns about data reporting and interpretation in “efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial”. J Psychiatr Res. 2012;46:692–693; author reply 4-5.
   PubMed Web of Science ®Google Scholar
• Tran P, Skolnick P, Czobor P, et al. Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Psychiatr Res. 2012;46:64–71.
   PubMed Web of Science ®Google Scholar
• Femenia T, Magara S, DuPont CM, et al. Hippocampal-dependent antidepressant action of the H3 receptor antagonist clobenpropit in a rat model of depression. Int J Neuropsychopharmacol. 2015;18.
   PubMed Web of Science ®Google Scholar
• Tiligada E, Kyriakidis K, Chazot PL, et al. Histamine pharmacology and new CNS drug targets. CNS Neurosci Ther. 2011;17:620–628.
   PubMed Web of Science ®Google Scholar
• Passani MB, Blandina P. Histamine receptors in the CNS as targets for therapeutic intervention. Trends Pharmacol Sci. 2011;32:242–249.
   PubMed Web of Science ®Google Scholar
• Ring RM, Regan CM. Captodiamine, a putative antidepressant, enhances hypothalamic BDNF expression in vivo by synergistic 5-HT2c receptor antagonism and sigma-1 receptor agonism. J Psychopharmacol. 2013;27:930–939.
   PubMed Web of Science ®Google Scholar
• Fava M, Johe K, Ereshefsky L, et al. A phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients. Molecular Psychiatry. 2016;21:1372-1380.
   Web of Science ®Google Scholar
• Fava M, Johe K, Ereshefsky L, et al. A phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients. Molecular Psychiatry. 2016;21:1483-1484.
   Web of Science ®Google Scholar
• Dos Santos RG, Osorio FL, Crippa JA, et al. Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. Ther Adv Psychopharmacol. 2016;6:193–213. .
   PubMed Web of Science ®Google Scholar
• Carhart-Harris RL, Goodwin GM. The therapeutic potential of psychedelic drugs: past, present, and future. Neuropsychopharmacology. 2017.
   Web of Science ®Google Scholar
• Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3:619–627.
   PubMed Web of Science ®Google Scholar
• Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30:1181–1197.
   PubMed Web of Science ®Google Scholar
• Osorio Fde L, Sanches RF, Macedo LR, et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. Rev Bras Psiquiatr. 2015;37:13–20.
   PubMed Web of Science ®Google Scholar
• Sanches RF, de Lima Osorio F, Dos Santos RG, et al. Antidepressant effects of a single dose of Ayahuasca in patients with recurrent depression: a SPECT study. J Clin Psychopharmacol. 2016;36:77–81.
   PubMed Web of Science ®Google Scholar
• dos Santos RG, Balthazar FM, Bouso JC, et al. The current state of research on Ayahuasca: a systematic review of human studies assessing psychiatric symptoms, neuropsychological functioning, and neuroimaging. J Psychopharmacol. 2016;30:1230–1247.
   PubMed Web of Science ®Google Scholar
• McCorvy JD, Olsen RH, Roth BL. Psilocybin for depression and anxiety associated with life-threatening illnesses. J Psychopharmacol. 2016;30:1209–1210.
   PubMed Web of Science ®Google Scholar
• Kellner CH, Fink M. Electroconvulsive therapy versus pharmacotherapy for bipolar depression. Am J Psychiatry. 2015;172:295.
   PubMed Web of Science ®Google Scholar
• Schoeyen HK, Kessler U, Andreassen OA, et al. Treatment-resistant bipolar depression: a randomized controlled trial of electroconvulsive therapy versus algorithm-based pharmacological treatment. Am J Psychiatry. 2015;172:41–51.
   PubMed Web of Science ®Google Scholar
• Kellner CH, Husain MM, Knapp RG, et al. A novel strategy for continuation ECT in geriatric depression: phase 2 of the PRIDE study. Am J Psychiatry. 2016;173:1110-1118.
   PubMed Web of Science ®Google Scholar
• Kellner CH, Husain MM, Knapp RG, et al. Right unilateral ultrabrief pulse ECT in geriatric depression: phase 1 of the PRIDE study. Am J Psychiatry. 2016;173:1101-1109.
   PubMed Web of Science ®Google Scholar
• Milev RV, Giacobbe P, Kennedy SH, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 4. neurostimulation treatments. Can J Psychiatry Revue Canadienne De Psychiatrie. 2016;61:561–575.
   PubMed Web of Science ®Google Scholar
• Dell’Osso B, Oldani L, Camuri G, et al. Augmentative repetitive Transcranial Magnetic Stimulation (rTMS) in the acute treatment of poor responder depressed patients: a comparison study between high and low frequency stimulation. Eur Psychiatry. 2015;30:271–276.
   PubMed Web of Science ®Google Scholar
• Dunner DL, Aaronson ST, Sackeim HA, et al. A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: durability of benefit over a 1-year follow-up period. J Clin Psychiatry. 2014;75:1394–1401.
   PubMed Web of Science ®Google Scholar
• Kedzior KK, Gellersen HM, Brachetti AK, et al. Deep transcranial magnetic stimulation (DTMS) in the treatment of major depression: an exploratory systematic review and meta-analysis. J Affect Disord. 2015;187:73–83.
   PubMed Web of Science ®Google Scholar
• Levkovitz Y, Isserles M, Padberg F, et al. Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial. World Psychiatry. 2015;14:64–73.
   PubMed Web of Science ®Google Scholar
• Leuchter AF, Cook IA, Feifel D, et al. Efficacy and safety of low-field synchronized Transcranial Magnetic Stimulation (sTMS) for treatment of major depression. Brain Stimul. 2015;8:787–794.
   PubMed Web of Science ®Google Scholar
• Rohan ML, Yamamoto RT, Ravichandran CT, et al. Rapid mood-elevating effects of low field magnetic stimulation in depression. Biol Psychiatry. 2014;76:186–193.
   PubMed Web of Science ®Google Scholar
• Yang C, Zhou ZQ, Gao ZQ, et al. Acute increases in plasma mammalian target of rapamycin, glycogen synthase kinase-3beta, and eukaryotic elongation factor 2 phosphorylation after ketamine treatment in three depressed patients. Biol Psychiatry. 2013;73:e35–e36.
   PubMed Web of Science ®Google Scholar
• Slyepchenko A, Carvalho AF, Cha DS, et al. Gut emotions - mechanisms of action of probiotics as novel therapeutic targets for depression and anxiety disorders. CNS Neurol Disord Drug Targets. 2014;13:1770–1786.
   PubMed Web of Science ®Google Scholar
• Garay RP, Zarate CA Jr., Charpeaud T, et al. Investigational drugs in recent clinical trials for treatment-resistant depression. Expert Rev Neurother. 2017;17:593–609. .
   PubMed Web of Science ®Google Scholar
• Bunney BG, Li JZ, Walsh DM, et al. Circadian dysregulation of clock genes: clues to rapid treatments in major depressive disorder. Molecular Psychiatry. 2015;20:48–55.
   PubMed Web of Science ®Google Scholar